STING1 and cancer: The STING agonist 5,6-dimethylfuranone-4-acetic acid (DMXAA) was originally developed by the Auckland Cancer Society Research Centre as an anti-cancer drug and later discovered to be a mouse STING(m-STING) molecular-specific agonist.